LVTX
NASDAQLAVA Therapeutics N.V.
Price$1.65+0.11 (+7.14%)
2025-08-212025-11-21
Latest news
25 items- SECAmendment: SEC Form 25-NSE/A filed by LAVA Therapeutics N.V.25-NSE/A - LAVA Therapeutics NV (0001840748) (Subject)
- SECSEC Form S-8 POS filed by LAVA Therapeutics N.V.S-8 POS - LAVA Therapeutics NV (0001840748) (Filer)
- SECSEC Form S-8 POS filed by LAVA Therapeutics N.V.S-8 POS - LAVA Therapeutics NV (0001840748) (Filer)
- SECAmendment: SEC Form SC 14D9/A filed by LAVA Therapeutics N.V.SC 14D9/A - LAVA Therapeutics NV (0001840748) (Subject)
- SECLAVA Therapeutics N.V. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Leadership Update8-K - LAVA Therapeutics NV (0001840748) (Filer)
- SECAmendment: SEC Form SC TO-T/A filed by LAVA Therapeutics N.V.SC TO-T/A - LAVA Therapeutics NV (0001840748) (Subject)
- PRXOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding common shares of LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) with a nominal value of €0.12 per share ("Shares"). LAVA shareholders received $1.04 in cash per Share and a non-transferrable contingent value right ("CVR") per Share representing the right to receive certain cash payments, including (A) the right to receive, among other things, 75% of any net proceeds related to LAVA's two partnered assets plus 75% of any net proceeds from any out license or sale of LAVA's unpart
- INSIDERChief Financial Officer Powell Fred M returned 65,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LAVA Therapeutics NV (0001840748) (Issuer)
- INSIDERSEC Form 4 filed by Director Oliger Christy J.4 - LAVA Therapeutics NV (0001840748) (Issuer)
- INSIDERSEC Form 4 filed by Director Wadlinger Mary E.4 - LAVA Therapeutics NV (0001840748) (Issuer)
- INSIDERDirector Wilson Karen J returned 10,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LAVA Therapeutics NV (0001840748) (Issuer)
- INSIDERDirector Dhingra Kapil returned 30,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LAVA Therapeutics NV (0001840748) (Issuer)
- INSIDERSEC Form 4 filed by Director Backstrom Jay T.4 - LAVA Therapeutics NV (0001840748) (Issuer)
- INSIDERSEC Form 4 filed by Director Noble James4 - LAVA Therapeutics NV (0001840748) (Issuer)
- INSIDERSEC Form 4 filed by Director Kiener Peter A4 - LAVA Therapeutics NV (0001840748) (Issuer)
- INSIDERChief Executive Officer Hurly Stephen A returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - LAVA Therapeutics NV (0001840748) (Issuer)
- SECAmendment: SEC Form SC 14D9/A filed by LAVA Therapeutics N.V.SC 14D9/A - LAVA Therapeutics NV (0001840748) (Subject)
- SECLAVA Therapeutics N.V. filed SEC Form 8-K: Leadership Update, Changes in Control of Registrant8-K - LAVA Therapeutics NV (0001840748) (Filer)
- PRLAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from NasdaqUTRECHT, The Netherlands, and PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced that 22,877,463 of LAVA's common shares, representing approximately 87% of LAVA's outstanding common shares, were validly tendered and not withdrawn prior to the expiration of the initial offering period one minute after 11:59 p.m. Eastern Time on November 12, 2025. As a result, the minimum tender condition and other conditions of the previously announced tender offer (the "Offer") of XOMA Royalty Corporation ("XOMA Royalty") to acquire LAVA have been satisfied. All validly tendered shares are expected to be accepted for payment on or about November 13
- SECAmendment: SEC Form SC TO-T/A filed by LAVA Therapeutics N.V.SC TO-T/A - LAVA Therapeutics NV (0001840748) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by LAVA Therapeutics N.V.SC 14D9/A - LAVA Therapeutics NV (0001840748) (Subject)
- PRLAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 DeadlineUTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced a reminder to LAVA shareholders related to the proposed transaction with XOMA Royalty Corporation ("XOMA") (NASDAQ:XOMA). On August 4, 2025, XOMA and LAVA announced they had entered into a share purchase agreement. More recently, on October 17, 2025, XOMA announced it had extended its offer (the "Offer") to purchase all outstanding common shares of LAVA until one minute after 11:59 p.m., Eastern time, on November 12, 2025 (the "Expiration Time"). LAVA would like to remind LAVA shareholders to tender their shares prior to the Expiration Time. If less t
- SECSEC Form 8-K filed by LAVA Therapeutics N.V.8-K - LAVA Therapeutics NV (0001840748) (Filer)
- SECSEC Form 10-Q filed by LAVA Therapeutics N.V.10-Q - LAVA Therapeutics NV (0001840748) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by LAVA Therapeutics N.V.SCHEDULE 13D/A - LAVA Therapeutics NV (0001840748) (Subject)
LVTX FAQ
7 questionsWhat does LAVA Therapeutics N.V. do?
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of...Where does LVTX stock trade?
LAVA Therapeutics N.V. (LVTX) is listed on NASDAQ.What sector and industry is LVTX in?
LAVA Therapeutics N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did LAVA Therapeutics N.V. go public?
LAVA Therapeutics N.V. (LVTX) completed its IPO in 2021.What are analysts saying about LVTX?
LAVA Therapeutics N.V. has had 5 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform with a $200.00 price target on 2024-12-12.What companies are similar to LVTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LVTX side-by-side with any of them on Quantisnow.How can I track LVTX on Quantisnow?
Quantisnow aggregates LAVA Therapeutics N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LVTX to receive live email and push alerts on every new disclosure.